In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.